2004, Number 2
<< Back Next >>
Gac Med Mex 2004; 140 (2)
A Guide for Osteoporosis Management.
Zárate A, Saucedo R, Basurto L
Language: Spanish
References: 33
Page: 235-240
PDF size: 443.53 Kb.
ABSTRACT
Osteoporosis has to be considered only as a risk factor for
bone fractures and its measurement by the bone mass index
has some limitations. The aim of treatment of osteoporosis is
to reduce the frequency of fractures (especially at the vertebral
and the hip) which are responsible for morbidity and mortality
with the osteoporosis. It has been demonstrated that
antiresorptive drugs (bisphosphonates, estrogens, raloxifen) as
well as anabolic agents (synthetic parathormone) are useful for
preventing fractures. Calcium and vitamin D supplementation
is not sufficient to treat persons with osteoporosis. Choice of
treatment depends of age, the presence or absence of prevalent
fractures, and the degree of bone mineral density measured
at the spine and hip. The main inconvenient for the adherence
of treatment is the high cost of the medicaments and agents
as well as the poor information given to the patients.
REFERENCES
Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929 -1936.
McGarry KA, Kiel DP. Postmenopausal osteoporosis: strategies for preventing bone loss, avoiding fracture. Postgraduate Med 2000;108:79-91.
Frost HM. Emerging views about "osteoporosis" bone health strength fragility, and their determinants. J Bone Miner Metab 2002;20 319-325
Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2026.
Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-650.
Kanis JA, Delmas P, Burckhardt P. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int 1997;7:390-346.
Gregg EW, Kriska AM, Salamone LM. The epidemiology of quantitative ultrasound: a review of the relationship with bone mass, osteoporosis and fracture risk. Osteoporosis Int 1997;7:89-99.
Zarate A, Basurto L, Saucedo R. Paradoja endocrinológica: los hombres necesitan estrógenos y las mujeres andrógenos. Ciencia 2003;51:5-11.
Bland R. Steroid hormone receptor expression and action in bone. Clin Science 2000;98:217-240.
Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2002;285:2891-97.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999; 6:273-276.
Marcus R, Wong M, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002;23:16-37.
Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporosis Int 2003;14:814-822.
Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-2202.
Riggs BL, Hartmann LC. Selective estrogen-receptor modulators. Mechanisms of action an application to clinical practice. New Eng J Med 2003;348:618-629.
Speroff L, Clarkson TB. Is tibolone a viable alternative to hormone therapy? Contemporary Ob Gyn 2003;48:54-68.
Prelevic GM, Markou A, Arnold A, Bartram C, Puzigaca Z, Ginsburg J. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteroporosis - 8 years follow-up. Maturitas 2004;47:229-234.
Black DM, Cummings SR, Karpf DB et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541.
Zárate A, Hernández M, Morán C, Angeles L. El enfoque moderno de la osteoporosis. Rev Fac Med UNAM 2003;46:49-51.
Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:108l-1082.
Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-276.
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-1941.
Holmes SJ, Shalet SM. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Hormone Res 1996;45:86-93.
Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nichgolson GC. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002;162:537-540.
Brudder JM, Mundy GR. Statins and their effects on bone formation. The Endocrinologist 2000;10:225-28
Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporosis fractures. J Bone Miner Res 1998;13:1755-1759.
Zárate A, MacGregor C, Basurto L. Fundamento del manejo de la osteoporosis en la menopausia para evitar el consumismo diagnóstico y terapéutico. Gac Méd Méx 1999;135:535-539.
Marshall D. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
Kamia JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-1936.
Gregg EW, Kriska AM, Salamone LM. The epidemiology of quantitative ultrasound: a review of the relationship with bone mass, osteoporosis and fracture risk. Osteoporosis Int 1997;7:89-99.
Bikle D. Biochemical markers in the assessment of bone disease. Am J Med 1997;103:427-436.
Basurto L, Saucedo R, Zárate A. Marcadores bioquímicos de remodelación ósea. Rev Med IMSS 2002;40:193-196.
Full text